|
시장보고서
상품코드
2032691
바이오테크놀러지 시약 시장 보고서 : 기술별, 용도별, 지역별(2026-2034년)Biotechnology Reagents Market Report by Technology (Life Science Reagents, Analytical Reagents), Application (Protein Synthesis and Purification, Gene Expression, DNA and RNA Analysis, Drug Testing, and Others), and Region 2026-2034 |
||||||
세계의 바이오테크놀러지 시약 시장 규모는 2025년에 982억 1,570만 달러에 이르렀습니다. IMARC Group은 향후 2034년까지 시장 규모가 1,802억 4,660만 달러에 이를 전망이며, 2026-2034년 CAGR 6.77%로 성장할 것으로 예측했습니다. 이 시장은 연구 개발 활동에 대한 투자 확대, 의료 진단 및 의약품 개발에 대한 수요 증가, 만성 및 유전성 질환의 유병률 증가, 생산 및 자동화의 급속한 기술 발전에 힘입어 견조한 성장세를 보이고 있습니다.
바이오테크놀러지 분야의 연구개발(R&D) 비용 증가
정부 및 민간 기업의 바이오테크놀러지 분야 연구개발(R&D) 지출 증가는 바이오테크놀러지 시약 산업의 성장을 가속하고 있습니다. 이 투자는 의료, 농업, 환경 보호에 대한 해결책을 제공할 수 있는 바이오테크놀러지의 잠재력을 인정받았기 때문입니다. 또한, 자금 증가로 인해 보다 광범위하고 집중적인 연구 프로젝트가 가능해졌고, 그 결과 많은 실험과 공정에 사용되는 시약에 대한 수요가 증가하고 있습니다. 예를 들어, 인도 브랜드 주식 재단(IBEF)의 2024년 최신 보고서에 따르면, 2023-24년도 연방 예산에서 인도 바이오테크놀러지국(DBT)은 연구개발(R&D), 농업 바이오테크놀러지 등의 추진을 위해 1억 6,270만 달러(1,340억 5,000만 루피)를 배정받았습니다.
만성질환 및 유전성 질환 증가
만성질환과 유전성 질환 증가는 바이오테크놀러지 산업이 새롭고 개선된 진단 및 치료 솔루션을 개발할 수 있는 동기를 부여하고 있습니다. 미국 질병예방통제센터(CDC) 보고서에 따르면 미국 성인 10명 중 6명이 만성질환을 앓고 있습니다. 또한 10명 중 4명은 2개 이상의 만성질환을 앓고 있습니다. 인도 노인의 약 21%가 적어도 한 가지 이상의 만성질환을 앓고 있는 것으로 보고되고 있습니다. 농촌 노인의 17%, 도시 노인의 29%가 적어도 한 가지 이상의 만성질환을 앓고 있습니다. 고혈압과 당뇨병은 모든 만성질환의 약 68%를 차지합니다. 이러한 의료 수요가 바이오테크놀러지용 시약 수요를 견인하고 있습니다. 이러한 시약은 분자 수준에서 질병 진단 및 유전자 치료법 개발에 필수적인 시약입니다.
제약 및 헬스케어 분야에서의 적용 확대
바이오테크놀러지 시약은 신약개발, 약물유전체학, 독성 시험에 활용되기 때문에 제약산업에서 없어서는 안 될 필수적인 존재입니다. 이 분야의 성장도 바이오테크놀러지 시약 시장의 매출 증가에 기여하고 있습니다. 의료비 증가, 인프라 개선, 인식의 향상으로 제약 분야는 놀라운 속도로 성장하고 있습니다. 예를 들어, 2030년까지 인도의 이 분야는 1,300억 달러 규모로 성장할 것으로 예측됩니다. 또한, 인도는 200여 개국 이상에 많은 의약품을 수출하고 있습니다. 아프리카 제네릭 의약품 수요의 50% 이상, 미국 제네릭 의약품 수요의 40%, 영국 전체 의약품의 25%를 공급하고 있습니다. 또한, 영국 제약업계의 매출액은 408억 파운드에 달할 전망입니다. 효과적인 치료제에 대한 수요 증가와 정확한 진단에 대한 관심 증가가 바이오테크놀러지 시약 시장 점유율 확대의 주요 요인으로 작용하고 있습니다.
The global biotechnology reagents market size reached USD 98,215.7 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,80,246.6 Million by 2034, exhibiting a growth rate (CAGR) of 6.77% during 2026-2034. The market is experiencing robust growth, driven by increasing investment in research and development (R&D) activities, rising demand in healthcare diagnostics and drug development, the heightened prevalence of chronic diseases and genetic disorders, and rapid technological advancements in production and automation.
Increasing Spending on Research and Development (R&D) in the Biotechnology Sector
The increase in research and development (R&D) spending within the biotechnology sector by governments and private entities is boosting the growth of the biotechnology reagents industry. This investment is driven by the recognition of biotechnology's potential to provide solutions in healthcare, agriculture, and environmental conservation. Also, increased funding allows for more extensive and intensive research projects, which, in turn, is responsible for raising the demand for reagents used in many experiments and processes. For example, in the Union Budget 2023-24, the Department of Biotechnology (DBT), India was allotted US$ 162.7 million (Rs. 1,345 crores) to promote R&D, agriculture biotechnology, and many more, according to the latest 2024 update by the India Brand Equity Foundation (IBEF).
Rising Prevalence of Chronic Diseases and Genetic Disorders
The increase in chronic diseases and genetic disorders has motivated the biotechnology industry to develop new and improved diagnostic and therapeutic solutions. 6 in 10 adults in the US are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions, based on the report by the Centers for Disease Control and Prevention. About 21% of the older adults in India reportedly have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. Hypertension and diabetes account for about 68% of all chronic diseases. This medical need is driving the demand for biotechnology reagents. They are vital in diagnosing conditions at the molecular level and creating genetic therapies.
Growing Applications in the Pharmaceutical and Healthcare Sectors
Biotechnology reagents are essential in the pharmaceutical industry as they are being utilized in drug discovery, pharmacogenomics, and toxicological testing. Growth in this sector is also contributing to the increased biotechnology reagent market revenue. The pharmaceutical sector is growing at an astonishing rate due to increased healthcare spending, better infrastructure, and greater awareness. For instance, by 2030, this sector in India is projected to grow to $130 billion. Additionally, India exports many medications to more than 200 nations. The country supplies over 50% of Africa's requirement for generics, 40% of generic demand in the US, and 25% of all medicine in the UK. Also, the pharmaceutical industry in the UK has a turnover of 40.8 billion pounds. The growing demand for effective therapeutic drugs and the rising emphasis on accurate diagnostics are key drivers of the rising biotechnology reagents market share.
As per the biotechnology reagent market analysis and outlook, the life science reagents segment is a significant part of the market, encompassing products used in molecular biology, cell biology, genetics, and other biomedical research fields. They are essential for a variety of applications, including deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) synthesis and purification, protein analysis, gene expression, and cell culture operations. Moreover, the increasing focus on research and development (R&D) in genomics and proteomics, advancements in molecular diagnostics, and the rising prevalence of chronic diseases that require novel therapeutic approaches are boosting the biotechnology reagents industry demand.
Based on the biotechnology reagents market trends and overview, analytical reagents form another crucial market segment and are predominantly used in chemical analysis, quality control, and clinical diagnostics. They are vital for spectrometry, chromatography, electrophoresis, and microscopy techniques. Analytical reagents benefit from the stringent regulatory requirements for product quality and safety in industries such as pharmaceuticals, food and beverage (F&B), and environmental testing.
As per the biotechnology reagent market segmentation, the protein synthesis and purification segment addresses the high demand for specialized reagents required in various processes involved in producing and isolating specific proteins. They are crucial in biotechnological applications such as enzyme production, pharmaceuticals, research pertaining to cellular functions, and diseases. Moreover, the widespread expansion of proteomics research and the increasing importance of biologic drugs in treatments, which rely heavily on the precise synthesis and purification of proteins, is favoring the market growth.
Based on the biotechnology reagents industry research, the gene expression segment encompasses reagents used in analyzing and quantifying gene expression levels within various cell types and conditions. It is essential in research areas like developmental biology, cancer research, and genetic disorder studies, where understanding gene activity is pivotal. Moreover, rapid advances in high-throughput technologies and the growing use of gene expression in personalized medicine to tailor treatments based on an individual's genetic makeup are enhancing the biotechnology reagent market value.
The deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analysis segment includes reagents used in genomic studies, such as sequencing, polymerase chain reaction (PCR) amplification, and molecular diagnostics. It is critical for advancing genetic research, identifying infectious diseases, and developing genetic markers in clinical diagnostics. Furthermore, the rapid advancements in genomic technologies, decreased sequencing costs, and the broader adoption of next-generation sequencing techniques across various fields, including forensic science, oncology, and microbiology, are bolstering the market growth.
Based on the biotechnology reagent market research report, the drug testing segment involves reagents used in pharmacological research to analyze the efficacy, stability, and safety of new drug compounds. It is vital in the preclinical and clinical stages of drug development. Additionally, the increasing global pharmaceutical R&D expenditures, the rising demand for new therapeutic drugs, and stringent regulatory standards requiring comprehensive drug testing are favoring the market growth.
North America leads the market, accounting for the largest biotechnology reagents market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for biotechnology reagents.
According to the biotechnology reagent market forecast, North America is the largest segment, driven by robust research infrastructure, substantial investments in biotechnology and pharmaceutical sectors, and the presence of leading biotech and healthcare companies. Moreover, the strong governmental support through funding and favorable regulatory policies aimed at advancing biotechnological research and healthcare innovations is catalyzing the market growth. Additionally, the rising adoption of advanced technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR), next-generation sequencing (NGS), and personalized medicine, is boosting the market growth. Besides this, the presence of a well-established academic and research environment, coupled with collaborations between research institutes and the biotechnology industry, is enhancing the market growth.